The purpose of the guideline is to make evidence-based recommendations for the application of blood grouping and red cell antibody testing in pregnancy. The aim is to predict the potential for, and where possible, prevent, haemolytic disease of the foetus and newborn (HDFN). The blood group and antibody status of a pregnant woman should be tested at booking and at 28 weeks' gestation to identify the ABO and D group and to detect red cell antibodies that have the potential to be clinically significant. Some antibodies (including anti-D, anti-K and anti-c) are associated with significant foetal and neonatal risks, such as anaemia, jaundice and perinatal loss. There are antibodies that are unlikely to significantly affect the foetus but that can cause neonatal anaemia and hyperbilirubinaemia, and others that may cause problems for the screening and timely provision of appropriate blood for the woman or baby. This guideline updates the previous British Society for Haematology (BSH) guidance published (2016) and is intended to incorporate necessary scope from the prior Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guidelines (2014) for the management of women with red cell antibodies during pregnancy. The testing protocols recommended here are designed to provide clarity for practice in order to protect pregnant women and their babies.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. All authors have made a declaration of interests to the BSH and Task Force Chairs, which may be viewed on request. The following authors Christoph Lees has undertaken Samsung, GE and Canon (speaker fees), Canon (research grant), Samsung & GE (webinars & research grant). The following members of the writing group Susan Robinson, Fiona Robinson, Edwin Massey, Fiona Regan, Janet Brennand, Tim Watts, Kirstin Finning, Katy Veale and Esther Southgate have no conflicts of interest to declare.